GLSI

Greenwich Lifesciences, Inc. (GLSI) - 10-K Summary

Business Context and Reporting Period

Company: Greenwich Lifesciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: GLSI is a clinical-stage biopharmaceutical company developing GLSI-100 (GP2 + GM-CSF), an immunotherapy designed to prevent breast cancer recurrence in HER2/neu-positive patients. The company is currently conducting the Phase III "Flamingo-01" clinical trial, expanding into Europe with plans for up to 150 global sites. The company has no approved products and has not generated any revenue to date.

Key Financial Metrics

Note: 2024 financial statements were restated to correct misstatements related to accounts payable and expense classification.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $1.9 million (11%) year-over-year, primarily driven by higher clinical expenses associated with the Phase III Flamingo-01 trial.
• Expense Growth: R&D expenses rose by $1.74 million (11%) due to trial expansion. G&A expenses increased slightly by $70,507 (3%).
• Capital Raising: In 2025, the company raised approximately $12.2 million in gross proceeds via At-The-Market (ATM) offerings and $145,000 from the exercise of remaining underwriter warrants. This contrasts with 2024, which included a $2.5 million private placement.
• Restatement: The company restated 2024 financials, increasing R&D expenses by $2.5 million and total liabilities by $1.6 million to account for previously unrecorded clinical trial expenses.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Liquidity: The company explicitly states it will require significant additional financing to fund operations and complete the development of GLSI-100. Management anticipates continuing to incur substantial losses for the foreseeable future. The auditor has issued a "Going Concern" opinion, noting that recurring losses raise substantial doubt about the company's ability to continue as a going concern without additional capital.

Key Risks and Contingencies:

• Capital Needs: No committed source of additional capital exists. Failure to raise funds could force delays or termination of clinical trials.
• Clinical Trial Risks: Success depends on the Flamingo-01 Phase III trial. Risks include patient enrollment difficulties, adverse events, and regulatory approval uncertainty.
• Manufacturing Dependence: The company relies on third-party manufacturers for the active pharmaceutical ingredient (API) and the GM-CSF adjuvant (single source supplier).
• Intellectual Property: The company relies on an exclusive license from the Henry M. Jackson Foundation (HJF). Termination of this license would halt development.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including inadequate segregation of duties and insufficient accounting systems.

Investor Verification Checklist

• Cash Runway: Verify current cash balance against the projected burn rate for the Phase III trial to assess immediate liquidity risk.
• Restatement Details: Review the specific nature of the 2024 restatement regarding the $1.6 million in unrecorded liabilities to ensure all accrued clinical costs are now properly captured.
• Capital Raise Status: Confirm the status of any new financing efforts post-filing, given the "Going Concern" warning and the need for funds to complete the Phase III trial.
• Internal Control Remediation: Monitor the company's progress in remedying the identified material weaknesses in financial reporting controls.
• Supply Chain Security: Assess the stability of the single-source supply agreement for GM-CSF, a critical component of the GLSI-100 therapy.